GenericDrugs News & Analysis
4 articles
Market Mood
Trump's Generic Drug Tariffs to Hit 100% by August 2028
President Donald Trump announced that generic drugs imported into the U.S. will face a 100% tariff starting in August 2028, rising to 200% in August 2029, after an initial two-year period with zero tariffs beginning August 1, 2026. This phased tariff schedule aims to incentivize domestic production of generic drugs. The U.S. imports nearly 50% of its generics from India, which significantly relies on the U.S. market for pharmaceutical exports. Ordinary investors should monitor these changes as they may impact the profitability and operations of major drugmakers like Eli Lilly and Pfizer (PFE).
Read More: Trump's Generic Drug Tariffs to Hit 100% by August 2028
US Supreme Court Supports Generic Drugmaker in Patent Case
The US Supreme Court upheld a decision favoring a generic drug manufacturer in a patent dispute involving 'skinny labels.' This ruling allows the sale of generic drugs that reference only certain indications of a patented drug, impacting the pharmaceutical industry. The decision is seen as significant in creating competition among drug manufacturers, potentially lowering prices. The outcome may influence market dynamics for both brand-name and generic drug companies, although specific companies and financial metrics were not disclosed.
Read More: US Supreme Court Supports Generic Drugmaker in Patent Case
Eli Lilly (LLY) market share drops to 56% in India as generics flood
Eli Lilly (LLY) saw its market share in India's GLP-1 weight-loss drug category decline to 56% in March from 61% in February, according to Pharmarack data. Meanwhile, Novo Nordisk (NVO) maintained a steady 25% market share despite the influx of generic semaglutide drugs following the expiration of its patent last month. The launch of 26 brands by 13 Indian generic companies is significantly impacting sales for Eli Lilly's higher-priced tirzepatide products. As generic options become more affordable, the competitive landscape for weight-loss treatment in India is changing rapidly, likely benefiting Novo Nordisk in the long run.
Read More: Eli Lilly (LLY) market share drops to 56% in India as generics flood
Strait of Hormuz Standoff Threatens U.S. Generic Drug Supply Chain
The ongoing standoff in the Strait of Hormuz poses a significant risk to the supply of generic drugs in the United States, as approximately 50% of these medications are manufactured in India and transported through this critical maritime route. This situation is particularly concerning as emergency preparedness in supply chains has limitations, and stockpiles of essential prescriptions may not suffice in the event of disruptions. The potential impact on the market could lead to price increases and shortages in the pharmaceutical sector, heightening concerns for consumers and healthcare providers alike.
Read More: Strait of Hormuz Standoff Threatens U.S. Generic Drug Supply Chain